Research progress on the application of monoclonal antibodies and antibody-drug conjugates in relapsed and refractory myeloma
Objective Multiple myeloma(MM)is a primary malignant tumor in the hematologic system,with most patients dying within years after diagnosis.In recent years,despite improvements in diagnostic and therapeutic methods,the incidence and mortality rates of MM remain high.For relapsed/refractory multiple myeloma(RRMM),the application of monoclonal antibodies(mAbs)and antibody-drug conjugates(ADCs)has offered new treatment options for patients.This article reviews the latest advancements in the treatment of RRMM with monoclonal antibodies Isatuximab,Daratumumab,Elotuzumab,and the antibody-drug conjugate Belantamab mafodotin,discussing their efficacy,indications,side effects,and management thereof.This review is based on the"Hong Kong Macau Medical Device Connect"policy.By analyzing the latest research results and clinical practice experience at home and abroad,it reviews the latest progress of monoclonal antibodies Isatuximab,Daratumumab,Elotuzumab,and antibody coupled drug Belantamab mafodotin in the treatment of RRMM,and discusses the efficacy,indications,side effects,and management methods of these treatment methods.It aims to offer references for treating RRMM patients and discusses the challenges and opportunities of current treatment strategies.
NETL
NSTL
万方数据
